Cellectis S.A. (EPA:ALCLS)

Market Cap	96.72M
Revenue (ttm)	50.65M
Net Income (ttm)	-56.00M
Shares Out	72.29M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,958
Average Volume	92,096
Open	1.340
Previous Close	1.338
Day's Range	1.312 - 1.356
52-Week Range	1.010 - 2.650
Beta	3.28
RSI	50.40
Earnings Date	May 7, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 222
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCLS

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD